Democratizing hedge fund level analysis tools for everyone
| Name | Darya-Varia Laboratoria Tbk. |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Health Care Research |
| Code | F2 |
| Latest Quarterly | 06-30-25 |
| Name | Latest % | A Month Ago % |
|---|---|---|
| Blue Sphere Singapore PT. Ltd | 92.12 | 92.12 |
| Public < 5% | 7.88 | 7.88 |
| Source | 2022 | 2021 |
|---|---|---|
| DVLA | F2 | Consumer Health Products |
| DVLA | F2 | Prescription Drugs |
| DVLA | F2 | Export & Toll |
| DVLA | F2 | Services |
| DVLA | F2 | Others |
| Region | 2022 | 2021 |
|---|---|---|
| DVLA | F2 | Indonesia |
| DVLA | F2 | International |
| DVLA | F2 | Others |
| Valuation | Ratio | Rank |
|---|---|---|
| P/S | 0.85 | # 6 / 15 |
| EV_EBITDA | 7.05 | # 3 / 15 |
| PER | 8.31 | --- / 15 |
| PBV | 1.18 | # 5 / 15 |
| DER | 0.56 | # 6 / 15 |
| Profitability | Ratio | Rank |
|---|---|---|
| NPM % | 10.093 | # 6 / 15 |
| ROA % | 9.180000000000001 | # 7 / 15 |
| ROE % | 13.900000000000002 | # 8 / 15 |
| Year | DPS | Yield [%] |
|---|---|---|
| 2024 | 216.0 | 13.6 |
| 2023 | 242.0 | 14.6 |
| 2022 | 232.0 | 9.8 |
| 2021 | 224.0 | 8.2 |
| 2020 | 214.0 | 8.8 |
| 2019 | 214.0 | 9.4 |
| 2018 | 74.0 | 3.2 |
| Timeframe | Performance |
|---|---|
| 1W % | 0.0 |
| 1Mo % | 0.0 |
| 3Mo % | 4.4 |
| 1Yr % | 6.8 |
| Stocks | PER | Market Cap | EV | Revenue | EBITDA | Net Profit |
|---|---|---|---|---|---|---|
| KLBF | 16.21 | 56.88 T | 58.14 T | 34,651 B | 5,348 B | 3,508 B |
| SOHO | 30.18 | 17.51 T | 19.64 T | 10,338 B | 711 B | 581 B |
| SIDO | 14.84 | 16.20 T | 15.77 T | 3,639 B | 1,481 B | 1,091 B |
| TSPC | 8.20 | 12.45 T | 10.93 T | 13,512 B | 2,016 B | 1,515 B |
| PYFA | -11.02 | 5.39 T | 11.42 T | 2,747 B | -142 B | -488 B |
| MDLA | 9.50 | 3.67 T | 6.27 T | 14,788 B | 557 B | 386 B |